According to the present clinical practice guidelines for IBD, therapeutic interventions mainly involve 5-aminosalicylic acid (ASA), corticosteroids, immunomodulators, antibiotics, probiotics, and anti-TNF agents. Here, TNF is linked to irritable bowel syndrome.